Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal Surgery: a Randomised Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Incisional pain is a common complication after surgery and is an important cause of delayed postoperative recovery, increased length of hospital stay, increased risk of wound infection and respiratory/cardiovascular complications, as well as an important medical, social, and economic problem. Prevention and treatment of postoperative incision pain remains challenging. Local Infiltration Anaesthesia (LIA) for surgical incisions with an anti-inflammatory and analgesic combination has been reported to be effective in reducing postoperative pain, but there is a gap in the research on the optimal concentration of anti-inflammatory drugs in the anti-inflammatory and analgesic combination during local infiltration. The aim of this study was to investigate the optimal concentration of anti-inflammatory drugs in the anti-inflammatory-analgesic combination solution used for local infiltration of spinal surgical incisions to prevent postoperative pain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Patients scheduled for spine surgery under general anesthesia. Anticipated cervical, thoracic, and lumbar spine surgeries (within three level).

• Patients age 18-65 years. American Society of Anaesthesiologists Classification of I or II.

Locations
Other Locations
China
Beijing Tiantan Hospital
RECRUITING
Beijing
Time Frame
Start Date: 2025-01-25
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 535
Treatments
Experimental: intervention group 1
0.012%diprospan+0.5%ropivacaine
Experimental: intervention group 2
0.009%diprospan+0.5%ropivacaine
Experimental: intervention group 3
0.006%diprospan+0.5%ropivacaine
Experimental: intervention group 4
0.003%diprospan+0.5%ropivacaine
Active_comparator: control group
0.5%ropivacaine
Related Therapeutic Areas
Sponsors
Leads: Beijing Tiantan Hospital

This content was sourced from clinicaltrials.gov